Skip to content
Head to head

Moderna vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: MRNA · VRTX

Updated 6 minutes ago

1-year performance, rebased to 100

MRNA +687.6%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
MRNAVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price195.00515.02
Change today-2.17%-1.08%
1-year return+772.1%+22.0%
Market cap$78.90B$130.58B
52-week range23.55 – 280.80412.27 – 568.67
Valuation
P/E (TTM)-27.7033.14
P/E percentile, own 5-yr range1st99th
P/B11.546.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-7.2615.32
Net profit (TTM)$-2.94B$3.88B
Revenue (TTM)$2.52B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+30.9%+11.8%
Gross margin27.9%85.5%
Operating margin-116.3%33.1%
Net margin-110.7%30.7%
Free cash flow (TTM)$-2.04B$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership78.3%96.8%
Insider activity (12mo)22 buy / 27 sell28 buy / 22 sell
Short interest (% of float)8.3%1.9%
Analyst consensus20% buy / 50% hold / 30% sell (10)95% buy / 5% hold (21)
Analyst price target$172 (-12%)$624 (+21%)
StockVane view
StockVane Quant RatingC (100)C (68)
Company
Employees4,7006,400
Founded20101989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.